Award-winning research points toward Alzheimer's vaccine

An accomplice to the protein that causes plaque buildup in Alzheimer’s disease is the focus of a potential new treatment, according to research by Georgia Health Sciences University graduate student, Scott Webster (pictured). Credit: Phil Jones, Georgia Health Sciences University photographer

An accomplice to the protein that causes plaque buildup in Alzheimer's disease is the focus of a potential new treatment, according to research by a Georgia Health Sciences University graduate student.

In Alzheimer's, the can accumulate in the brain instead of being eliminated by the body's natural defenses, between the neurons and forming impassable plaques.

Amyloid and the way it gets there could be targets for a new .

"RAGE, or receptor for advanced glycation endproducts, proteins bind to amyloid and transport it into the brain," said Scott Webster, a fifth-year graduate student who is studying the disease in the lab of Dr. Alvin Terry, Professor of Pharmacology and Toxicology. Research has shown that RAGE may also contribute to the inflammation and damage that amyloid causes to the brain's .

Webster is researching a vaccine that targets RAGE and amyloid by using the body's own immune system to protect against their over-production and eventual build-up. His work has earned him the 2011 Darrell W. Brann Scholarship in Neuroscience, a $1,000 award honoring an outstanding graduate student on campus working in neuroscience.

"Unfortunately, all of the vaccines for Alzheimer's that have been through clinical trials have failed," he said. "Part of the reason why could be that they're just not comprehensive enough. Most only amyloid. Our hope is that by taking a more encompassing approach, we will be more effective. So far, that's exactly what we're seeing in our experiments."

Other vaccines also have multiple side effects, including swelling of the brain. Webster hopes that targeting the RAGE protein and changing how the vaccine is administered will minimize inflammatory side effects.

Another benefit is that the vaccine can be administered orally, since it does not require an , which is added to vaccines to enhance the . The is one of the body's largest repositories of human flora, microorganisms that are key to the immune system.

"That's a relatively new idea," Webster said. "By using the immune system that's endogenous to our gut, we can skew the body's response away from the inflammatory and toward a more robust antibody response, bypassing some of the side effects."

Early results have shown improved cognition and memory in animal models of Alzheimer's, something Webster considers a sort of personal crusade.

"I have watched a close family friend suffer from the disease and saw how devastating it was," he said. "The family is caring for this person and yet the person doesn't even remember who his own family is. It's a heartbreaking process to watch."

Even with promising results, he cautioned of unknowns about the potential vaccine.

"We need to move on to larger animal studies. We have a lot we still don't know about the vaccine itself. For example, we know that amyloid and RAGE bind together, but we don't know why the binding creates such a stable complex. We have these end points, but we still don't know some of the basic science that needs to be known so that we can push ahead."

Related Stories

Researchers create experimental vaccine against Alzheimer's

date Oct 08, 2010

Researchers at UT Southwestern Medical Center have created an experimental vaccine against beta-amyloid, the small protein that forms plaques in the brain and is believed to contribute to the development of Alzheimer's disease.

Development of a safer vaccine for Alzheimer’s disease

date Nov 17, 2010

A new vaccine protects against memory problems associated with Alzheimer's disease, but without potentially dangerous side effects, a new animal study reports. The research was presented at Neuroscience 2010, the annual meeting ...

Study suggests blood test for Alzheimer's possible

date Mar 11, 2009

Researchers have revealed a direct relationship between two specific antibodies and the severity of Alzheimer's disease symptoms, raising hopes that a diagnostic blood test for the devastating disorder is within reach.

Vaccine triggers immune response, prevents Alzheimer's

date May 19, 2008

A vaccine created by University of Rochester Medical Center scientists prevents the development of Alzheimer’s disease-like pathology in mice without causing inflammation or significant side effects.

Recommended for you

Altered pain processing in patients with cognitive impairment

date 20 hours ago

People with dementia and other forms of cognitive impairment (CI) have altered responses to pain, with many conditions associated with increased pain sensitivity, concludes a research review in Pain, the official publication of the ...

Changing activity in the ageing brain

date May 29, 2015

Normal ageing affects our ability to carry out complex cognitive tasks. But exactly how our brain functions change during this process is largely unknown. Now, researchers in Malaysia have demonstrated that ...

Networking neurons thrive in 3-D human 'organoid'

date May 29, 2015

A patient tormented by suicidal thoughts gives his psychiatrist a few strands of his hair. She derives stem cells from them to grow budding brain tissue harboring the secrets of his unique illness in a petri ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.